CircBIRC6 facilitates the malignant progression via miR-488/GRIN2D-mediated CAV1-autophagy signal axis in gastric cancer
- Pharmacol Res. 2024 Mar 2:202:107127. doi: 10.1016/j.phrs.2024.107127.
- 1. Department of Clinical Biobank, Department of Pharmacy, Affiliated Hospital of Nantong University & Department of Pathology, Medical School of Nantong University, Nantong 226001, China.
- 2. Laboratory Medicine Center, Affiliated Hospital of Nantong University, Nantong 226001, China.
- 3. MOE Frontier Science Centre for Precision Oncology, University of Macau, Macau. Electronic address: [email protected].
- 4. Department of General Surgery, Affiliated Hospital of Nantong University, Nantong 226001, China. Electronic address: [email protected].
- 5. Department of Clinical Biobank, Department of Pharmacy, Affiliated Hospital of Nantong University & Department of Pathology, Medical School of Nantong University, Nantong 226001, China. Electronic address: [email protected].
Circular RNAs (circRNAs) represent a novel class of non-coding RNAs that play significant roles in tumorigenesis and tumor progression. High-throughput Sequencing of Gastric Cancer (GC) tissues has identified circRNA BIRC6 (circBIRC6) as a potential circRNA derived from the BIRC6 gene, exhibiting significant upregulation in GC tissues. The expression of circBIRC6 is notably elevated in GC patients. Functionally, it acts as a molecular Sponge for miR-488, consequently upregulating GRIN2D expression and promoting GC proliferation, migration, and invasion. Moreover, overexpression of circBIRC6 leads to increased GRIN2D expression, which in turn enhances caveolin-1 (CAV1) expression, resulting in Autophagy deficiency due to miR-488 sequestration. This cascade of events significantly influences tumorigenesis in vivo. Our findings collectively illustrate that the CircBIRC6-miR-488-GRIN2D axis fosters CAV1 expression in GC cells, thereby reducing Autophagy levels. Both circBIRC6 and GRIN2D emerge as potential targets for treatment and independent prognostic factors for GC patients.
-
Cat. No.Product NameCategory/Application